Mifepristona Linepharma (Mifepristone)

Mifepristone, the active ingredient in Mifepristona Linepharma, is a progesterone receptor antagonist presented as an oral tablet for oral use. It is employed for medical termination of pregnancy and for the management of Cushing's syndrome in appropriately selected patients.

GNH USA supplies Mifepristona Linepharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifepristone acts on progesterone‑dependent pathways and is indicated for the following clinical situations:

- Medical termination of pregnancy: induces decidual breakdown and uterine contractility to facilitate pregnancy termination. - Cushing's syndrome: antagonizes glucocorticoid receptors to help control hypercortisolism.

Mifepristone may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional episodes after dosing. - Abdominal pain or cramping: uterine discomfort. - Vaginal bleeding: spotting or heavier flow. - Fatigue: general tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe infection: signs of sepsis. - Heavy or prolonged bleeding: may require medical attention. - Allergic reaction: rash, itching, swelling. - Liver toxicity: elevated enzymes or jaundice. - Adrenal insufficiency: signs of cortisol deficiency. - Rare cardiovascular events: hypertension or thromboembolism.

Before prescribing Mifepristona Linepharma, clinicians should consider several safety measures. - Gestational age verification: confirm eligibility for medical abortion. - Medical supervision: ensure administration under qualified health‑care provider. - Adrenal function assessment: evaluate for potential insufficiency. - Concomitant medication review: check for interactions that may alter efficacy. - Contraindication screening: avoid in ectopic pregnancy or severe bleeding disorders. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Mifepristona Linepharma can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Rifampin: induces hepatic metabolism, reducing effectiveness. - Carbamazepine: strong enzyme inducer, may lower drug levels. - St. John's wort: herbal inducer, can decrease exposure. - Ketoconazole: potent CYP3A4 inhibitor, may increase toxicity. - Antifungal azoles (e.g., itraconazole): can raise plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may alter bleeding risk. - Antidepressants (SSRIs): monitor for additive side effects. - Antihypertensives: watch for blood pressure changes. - NSAIDs: increased risk of gastrointestinal irritation. - Hormonal contraceptives: possible reduced efficacy.